• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Doximity (DOCS) Valuation Check After Q2 Beat, AI Growth Momentum and Cautious Policy-Driven Outlook

    Simply Wall St·12/08/2025 16:12:41
    Listen to the news

    Doximity (DOCS) just posted second quarter results that topped forecasts on both earnings and revenue, with roughly 23% growth powered by its AI workflow tools, even as management flagged policy driven client budget uncertainty.

    See our latest analysis for Doximity.

    Despite the upbeat quarter, Doximity’s share price return has been under pressure, with a roughly 34% 3 month slide and negative 1 year total shareholder return. However, the 3 year total shareholder return remains firmly positive, hinting at longer term confidence that near term volatility could be temporary.

    If this mix of volatility and growth potential has your attention, it might be a good time to explore other healthcare names through healthcare stocks and compare how they stack up on fundamentals.

    With Doximity trading well below analyst price targets yet still posting double digit growth and elite margins, are investors overlooking a profitable healthcare platform, or is the market already pricing in its next leg of AI fueled expansion?

    Most Popular Narrative: 35.4% Undervalued

    With Doximity closing at $45.93 against a narrative fair value of $71.11, the valuation gap rests on how durable its growth and margins prove to be.

    The expanded adoption of AI powered workflow tools (Scribe, Doximity GPT, and Pathway AI) is expected to further entrench Doximity as a core clinician productivity suite. This may drive frequency of platform use, deepen customer retention, and ultimately support higher average revenue per user (ARPU) over time, along with long term revenue and margin expansion.

    Read the complete narrative.

    Want to see why this story leans heavily on rising revenue, resilient margins, and a punchy future earnings multiple, all pulling in the same direction? Dig into the full narrative to unpack the specific growth path and profit assumptions that underpin that higher fair value.

    Result: Fair Value of $71.11 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, there are still meaningful risks, including pharma marketing budget cuts and slower monetization of free AI tools, that could challenge this upbeat view.

    Find out about the key risks to this Doximity narrative.

    Build Your Own Doximity Narrative

    If you see things differently or simply want to dig into the numbers yourself, you can build a personalized view in under three minutes, Do it your way.

    A good starting point is our analysis highlighting 4 key rewards investors are optimistic about regarding Doximity.

    Looking for more investment ideas?

    Before you move on, consider your next move by using the Simply Wall St Screener to uncover fresh, high conviction stocks that others are missing.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.